Overview

Psychopharmacological Treatment of Emotional Distress

Status:
Recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
This is an inpatient four-arm randomized control trial comparing single drug clonazepam (S arm), a two-drug combination clonazepam/olanzapine (D arm), and a three-drug combination clonazepam/olanzapine/buprenorphine (T arm) with treatment as usual (TAU arm) in the treatment of emotional distress, specifically the Suicide Crisis Syndrome (SCS). All participants in experimental arms receive 2-day pulse treatments targeting four out of five of the acute emotional distress symptoms. The primary outcome measure is SCS at discharge and one-month follow-up. The secondary outcome measures include questions about suicidal behaviors associated with emotional distress at a one-month follow-up.
Phase:
Phase 4
Details
Lead Sponsor:
Icahn School of Medicine at Mount Sinai
Treatments:
Buprenorphine
Clonazepam
Olanzapine